The HCV NS5A Drug Resistance Assay is a genotypic (sequencing) resistance assay that analyzes the nonstructural (NS) 5A region of hepatitis C virus (HCV) genotypes 1a or 1b using next-generation sequencing (NGS) techniques. Amino acid substitutions in the NS5A region are identified, and a viral susceptibility call for the direct-acting agents (DAAs) that inhibit the NS5A proteins is reported as either “resistance possible” or “none/undetermined”. Monogram offers NS5A testing for both HCV genotype 1 and HCV genotype 3 viruses.
Features of HCV NS5A Drug Resistance Assay
- Assessment of HCV susceptibility for currently available NS5A DAAs, including daclatasvir, elbasvir, ledipasvir and ombitasvir for HCV genotype 1 viruses
- Assessment of velpatasvir for HCV genotypes 1 and 3
- Assessment of daclatasvir susceptibility for HCV genotype 3 patients
- Identification of amino acid variants within the NS5A protein of HCV genotypes 1a or 1b, or genotype 3
- Detection of mixtures of wild-type and drug-resistant variants when present at levels as low as 10% of the total population